complement

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

Complement C1s-IN-1 is a potent and selective inhibitor of complement C1s with the advantage of being orally available and brain penetrable, significantly inhibiting human serum-induced formation of membrane attack complexes in a dose-dependent manner and effectively blocking the classical complement pathway

Complement factor D-IN-1 is a potent and selective small-molecule reversible Factor D inhibitor, with IC50 values of 0.006 μM in the FD Thioesterolytic Fluorescent Assay and 0.05 μM in the MAC Deposition Assay.

Complement factor D-IN-2 is an inhibitor that reduces the excessive activation of Complement factor D.

Complement factor I, a serine protease, attenuates complement activity both in the fluid phase and on cell surfaces, working alongside cofactors such as factor H (FH), complement receptor 1 (CR1 CD35), C4 binding protein (C4BP), or membrane cofactor protein (MCP CD46) [1].

Cyclosporin A is a naturally occurring cyclic polypeptide that is the active metabolite of a fungus. Cyclosporin A is an immunosuppressant that binds to procyclins and inhibits calcineurin (IC50=7 nM).

Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory and immunosuppressive properties that induces autophagy and inhibits LPS-induced inflammatory responses in macrophages.

EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 μM and an IC50 value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.EG01377 exhibits anti-angiogenic, antimigratory and antitumor activities.

BCX 1470 hydrochloride is a potent serine protease inhibitor with anti-inflammatory activity that inhibits the ester hydrolysis and haemolytic activity of factor D and C1s, and can be used to study oedema.

DiMNF (3',4'-Dimethoxy-αNF) is a selective and potent modulator of the aryl hydrocarbon receptor (AHR) and an AHR ligand with anti-inflammatory activity that inhibits cytokine-mediated induction of complement factor genes.

AA 2379 is an orally available antirheumatic agent with anti-inflammatory and antipyretic activity that dose-dependently inhibits complement-mediated yeast glycan-induced paw edema in rats and yeast glycan-activated serum-induced peritonitis in mice.

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

3-Phenoxybenzaldehyde is a complement (classical pathway) inhibitor with IC50 of 1388μM.

Factor B-IN-5 is a complement factor B inhibitor, which can be used to study immune-related diseases.

TLQP 21 acetate is a potent agonist of G-protein-coupled receptor complement-3a receptor 1 (C3aR1). The EC50 values are 10.3 μM for mouse and 68.8 μM for human. TLQP 21 acetate is a VGF-derived peptide with endocrine and extraendocrine properties.

W-54011 is a potent non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils (Ki: 2.2 nM). W-54011 inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of ROS in human neutrophi

Avacopan (CCX168) is a C5aR antagonist (IC50=0.1 nM) with selective and oral activity. Avacopan blocks the action of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a mouse model of AAV. Avacopan can be used to treat anti-neutrophil cytoplasmic antibody (ANCA)-related vasculitis.

FD-IN-1 is a factor D (FD) inhibitor with an IC50 of 12 nM.FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5μM, respectively. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system.

Protoporphyrin IX (PPIX) is a tetrapyrrole that is a metabolic precursor of heme, cytochrome c, and chlorophyll. Protoporphyrin IX has been shown to improve liver function, promote cellular tissue respiration, improve protein and glucose metabolism, and resist complement binding.

PMX 205 Trifluoroacetate is a potent complement antagonist of C5a receptor.

PMX 205 is an effective complement antagonist of the C5a receptor.

PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88).

SB290157 trifluoroacetate is a potent and selective antagonist of the C3a receptor, with an IC50 of 200 nM.